Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis (DOAC-CVT)
About the study
DOAC-CVT is an international, prospective, phase IV cohort study investigating the safety and efficacy of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in the treatment of cerebral venous thrombosis.
Patients may be included if they fulfill the following criteria:
-
Age >18 years at the time of CVT diagnosis
-
Radiologically confirmed CVT diagnosis (CT-venography, MRI or catheter angiography)
-
Oral anticoagulant treatment (DOAC or VKA) started within 30 days of CVT diagnosis (patient may initially be treated with heparin)
-
Informed consent for the use of coded data if required by local law.
Exclusion criteria are:
-
Anticoagulant treatment at the time of CVT diagnosis
-
Absolute contra-indication for use of DOACs:
-
Pregnancy or lactation (post-partum women are eligible if they do not give breast-feeding)
-
Mechanical heart valve
-
Severe renal insufficiency (defined as an eGFR <15 ml/min)
-
Severe liver disease resulting in clinically relevant coagulopathy
-
For more details about the study, please see the recently published Study Protocol Paper: Frontiers | Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis (DOAC-CVT) -A Protocol of an International Phase IV Study (frontiersin.org)
Status of the study
Please find below the September 2023 issue of the DOAC-CVT Newsletter with the most recent updates on the study:
We are still recruiting new centers for study participation. If you would like to participate in this research project, please e-mail the project leader Dr. Jonathan Coutinho.
Data collection
Please click on the button below to access the electronic database (Castor EDC). Access to the online CRF must be provided by the study coordinators.